Back to top

crispr: Archive

Zacks Equity Research

Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss

Allogene's (ALLO) fourth-quarter earnings beat estimates, but sales miss the mark. Management expects operating expenses for 2024 to be around $280 million.

GSKPositive Net Change ANIPPositive Net Change ADMAPositive Net Change ALLOPositive Net Change

Zacks Equity Research

Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology

Allogene (ALLO) intends to combine its next generation AlloCAR T platform with Arbor Biotechnologies' proprietary CRISPR gene therapy technology to develop therapies for autoimmune diseases.

GSKPositive Net Change ANIPPositive Net Change ADMAPositive Net Change ALLOPositive Net Change